MedImmune Expands Scientific and Engineering ...(f biopharmaceutical development in 2004....),Health

Date:12/20/2007

f biopharmaceutical development in 2004. Previously, Dr. Varley was head of protein science at British Biotech from 1993-1998 and had served as a staff scientist at the National Institute of Biological Standards and Control, UK. He has also undertaken post-doctoral research at the University of Newcastle upon Tyne and at the U.S. National Institutes of Health. Dr. Varley holds a degree in biomolecular sciences from Portsmouth Polytechnic and a doctorate from the University of Newcastle upon Tyne.

Andy Williams, Ph.D., vice president, research, project management joined CAT in 1993 following a post-doctoral fellowship at University of British Columbia in Vancouver in which he had continued the work on the molecular genetics of color vision he had initiated while pursuing his doctorate at Queen Mary and Westfield College, University of London. Dr. Williams has led a number of drug discovery and technology development projects at CAT while previously serving as head of target validation and later establishing the project management and planning group within drug discovery. He holds a first degree in biochemistry from Kings College, University of London.

Trevor Boulding, director, human resources (HR), joined CAT in January 2005 after many years of senior-level HR experience in hi-tech manufacturing and broadcasting. Under his direction, the organization in Cambridge has revised its employee performance management and remuneration systems, implemented a flexible benefits scheme and met the resourcing needs of the plan for biologics growth. Mr. Boulding holds a bachelor's degree in Spanish and French from Birmingham University and is a member of the Institute of Personnel Management (now the Chartered Institute of Personnel & Development).

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters
'/>"/>

SOURCE MedImmune Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
4. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
5. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
8. Rohm and Haas Expands in India
9. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
10. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
11. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors